Related Experiment Video
Updated: Feb 22, 2026
Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model
Published on: October 2, 2015
Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model
Janne Nestvold1, Meng-Yu Wang2,3, Ketil A Camilio2,4
1Department of Transplantation Medicine, Institute for Surgical Research, Oslo University Hospital, NO-0732 Oslo, Norway.
Abstract:
LTX 315 is an oncolytic peptide with potent immunological properties. In the present study, we demonstrate that intratumoral treatment with LTX-315 resulted in a complete regression and systemic immune response in a rat fibrosarcoma model. The treatment was T-cell dependent, and also resulted in an abscopal effect as demonstrated by the regression of distal non-treated lesions. Significant infiltration of CD8+ T cells was observed in both treated and non-treated lesions, as shown by immunohistochemical and flow cytometric analysis. LTX-315 rapidly killed the cells in vitro with a lytic mode of action followed by the subsequent release of Danger-Associated Molecular Pattern (DAMP) molecules such as HMGB1, ATP and Cytochrome c. Together, our data demonstrate that LTX-315 represents a new approach to cancer immunotherapy, which has the potential as a novel immunotherapeutic agent.
Insights
LTX-315, an oncolytic peptide, triggers a T-cell dependent immune response leading to complete tumor regression and abscopal effects in a fibrosarcoma model. This novel cancer immunotherapy agent shows significant potential.
Area of Science:
- Oncology
- Immunology
- Peptide Therapeutics
Background:
- Oncolytic peptides are emerging as a promising class of anti-cancer agents.
- LTX-315 is an investigational oncolytic peptide with known immunological properties.
Purpose of the Study:
- To evaluate the efficacy of intratumoral LTX-315 treatment in a preclinical cancer model.
- To investigate the immunological mechanisms underlying LTX-315's anti-tumor activity.
Main Methods:
- Intratumoral administration of LTX-315 in a rat fibrosarcoma model.
- Assessment of tumor regression, systemic immune response, and T-cell infiltration (CD8+).
- In vitro cell killing assays and analysis of Danger-Associated Molecular Pattern (DAMP) molecule release.
Main Results:
- LTX-315 induced complete tumor regression and a systemic immune response.
- A T-cell dependent mechanism and abscopal effect (regression of non-treated lesions) were observed.
- Significant infiltration of CD8+ T cells into both treated and non-treated tumors.
- LTX-315 demonstrated rapid in vitro cell lysis and release of DAMPs (HMGB1, ATP, Cytochrome c).
Conclusions:
- LTX-315 exhibits potent anti-tumor activity through direct cell lysis and immune stimulation.
- The T-cell mediated response and DAMP release contribute to LTX-315's oncolytic and immunotherapeutic effects.
- LTX-315 represents a novel immunotherapeutic agent with potential for cancer treatment.
